|Stage of funding:||Current|
|Therapeutic group:||Inflammatory Diseases|
Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. The company is building a sustainable pipeline of first-in-class immuno-modulators .
The lead drug candidate, CTX-4430, is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in the production of the powerful promoter of inflammation Leukotriene B4 (LTB4). Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). CTX-4430 has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients.
CTX-4430 will also be advanced into a phase II trial in moderately severe acne, a disorder characterized by a high expression of LTB4. It is one of a series of candidates covered under composition of matter patents being developed by Celtaxsys.
Celtaxsys is located in Atlanta, GA with a subsidiary office in Brisbane, Queensland, Australia.
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
15 September 2017
14 September 2017
11 September 2017